Sales & Marketing News | pharmaphorum

News

Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics.

News

The EMA has abandoned X for Bluesky, saying Elon Musk's social media platform "no longer suits our communication needs."

News

Lyfegen and EVERSANA have joined forces to help pharma companies navigate an increasingly complex global drug pricing and access environment.

News

Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.

News

Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

News

Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company.